Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review

Overview

Journal Neurol Med Chir (Tokyo)

Specialties Neurology
Neurosurgery

Date 2022 Jul 24

PMID 35871574

Authors

Atsushi Okano

Satoru Miyawaki

Yu Teranishi

Kenta Ohara

Hiroki Hongo

Yu Sakai

Daiichiro Ishigami

Hirofumi Nakatomi

Nobuhito Saito

Affiliations

Soon will be listed here.

Abstract

The treatment of World Health Organization (WHO) grades 2 and 3 meningiomas remains difficult and controversial. The pathogenesis of high-grade meningiomas was expected to be elucidated to improve treatment strategies. The molecular biology of meningiomas has been clarified in recent years. High-grade meningiomas have been linked to NF2 mutations and 22q deletion. CDKN2A/B homozygous deletion and TERT promoter mutations are independent prognostic factors for WHO grade 3 meningiomas. In addition to 22q loss, 1p, 14p, and 9q loss have been linked to high-grade meningiomas. Meningiomas enriched in copy number alterations may be biologically invasive. Furthermore, several new comprehensive classifications of meningiomas have been proposed based on these molecular biological features, including DNA methylation status. The new classifications may have implications for treatment strategies for refractory aggressive meningiomas because they provide a more accurate prognosis compared to the conventional WHO classification. Although several systemic therapies, including molecular targeted therapies, may be effective in treating refractory aggressive meningiomas, these drugs are being tested. Systemic drug therapy for meningioma is expected to be developed in the future. Thus, this review aims to discuss the distinct genomic alterations observed in WHO grade 2 and 3 meningiomas, as well as their diagnostic and therapeutic implications and systemic drug therapies for high-grade meningiomas.

Citing Articles

A novel compound, SYHA1813, inhibits malignant meningioma growth directly by boosting p53 pathway activation and impairing DNA repair.

Lan Y, Li S, Wang J, Yang X, Wang C, Huang M Front Oncol. 2025; 15:1522249.

PMID: 40052125 PMC: 11882425. DOI: 10.3389/fonc.2025.1522249.

Spontaneous regression of a petroclival meningioma: illustrative case.

Noda R, Kawashima M, Akabane A, Inoue T J Neurosurg Case Lessons. 2024; 8(15).

PMID: 39378522 PMC: 11465344. DOI: 10.3171/CASE24416.

Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study.

Nguyen P, Roland N, Neumann A, Hoisnard L, Passeri T, Duranteau L Lancet Reg Health Eur. 2024; 42:100928.

PMID: 38800110 PMC: 11127190. DOI: 10.1016/j.lanepe.2024.100928.

DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas.

Kim J, Chang S, Haghdel A, Ramakrishna R, Pannullo S, Schwartz T AJNR Am J Neuroradiol. 2024; 45(6):773-780.

PMID: 38604734 PMC: 11288599. DOI: 10.3174/ajnr.A8219.

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo.

Mitobe Y, Suzuki S, Nakagawa-Saito Y, Togashi K, Sugai A, Sonoda Y Biomedicines. 2023; 11(7).

PMID: 37509605 PMC: 10377688. DOI: 10.3390/biomedicines11071967.

References

Preusser M, Spiegl-Kreinecker S, Lotsch D, Wohrer A, Schmook M, Dieckmann K . Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. 2012; 118(20):5038-49. DOI: 10.1002/cncr.27460. View

Stogbauer L, Stummer W, Senner V, Brokinkel B . Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review. Neurosurg Rev. 2019; 43(3):903-910. DOI: 10.1007/s10143-019-01087-3. View

Korver W, Schilham M, Moerer P, van den Hoff M, Dam K, Lamers W . Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident. Curr Biol. 1998; 8(24):1327-30. DOI: 10.1016/s0960-9822(07)00563-5. View

Bi W, Nayak L, Meredith D, Driver J, Du Z, Hoffman S . Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2021; 24(1):101-113. PMC: 8730772. DOI: 10.1093/neuonc/noab118. View

Collord G, Tarpey P, Kurbatova N, Martincorena I, Moran S, Castro M . An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Sci Rep. 2018; 8(1):13537. PMC: 6131140. DOI: 10.1038/s41598-018-31659-0. View

Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J . TERT Promoter Mutations and Risk of Recurrence in Meningioma. J Natl Cancer Inst. 2015; 108(5). PMC: 4849806. DOI: 10.1093/jnci/djv377. View

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

Choudhury A, Raleigh D . Preclinical models of meningioma: Cell culture and animal systems. Handb Clin Neurol. 2020; 169:131-136. DOI: 10.1016/B978-0-12-804280-9.00008-1. View

Deng J, Sun S, Chen J, Wang D, Cheng H, Chen H . Alterations Predict Tumor Progression in High-Grade Meningiomas Following Adjuvant Radiotherapy. Front Oncol. 2021; 11:747592. PMC: 8586415. DOI: 10.3389/fonc.2021.747592. View

10.

Nassiri F, Wang J, Singh O, Karimi S, Dalcourt T, Ijad N . Loss of H3K27me3 in meningiomas. Neuro Oncol. 2021; 23(8):1282-1291. PMC: 8328029. DOI: 10.1093/neuonc/noab036. View

11.

Katz L, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R . Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018; 135(6):955-963. DOI: 10.1007/s00401-018-1844-9. View

12.

Du Z, Abedalthagafi M, Aizer A, Mchenry A, Sun H, Bray M . Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015; 6(7):4704-16. PMC: 4467109. DOI: 10.18632/oncotarget.3082. View

13.

Laurendeau I, Ferrer M, Garrido D, DHaene N, Ciavarelli P, Basso A . Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med. 2010; 16(7-8):262-70. PMC: 2896461. DOI: 10.2119/molmed.2010.00005. View

14.

Tien A, Li J, Bao X, Derogatis A, Kim S, Mehta S . A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. Clin Cancer Res. 2019; 25(19):5777-5786. PMC: 6863147. DOI: 10.1158/1078-0432.CCR-19-0133. View

15.

Shankar G, Abedalthagafi M, Vaubel R, Merrill P, Nayyar N, Gill C . Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017; 19(4):535-545. PMC: 5464371. DOI: 10.1093/neuonc/now235. View

16.

Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, Quentin S, El-Taraya N, Walczak C . Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene. 2012; 32(36):4264-72. DOI: 10.1038/onc.2012.436. View

17.

Rogers L, Gilbert M, Vogelbaum M . Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010; 99(3):393-405. DOI: 10.1007/s11060-010-0343-1. View

18.

Schulz C, Mathieu R, Kunz U, Mauer U . Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011; 30(5):E11. DOI: 10.3171/2011.1.FOCUS111. View

19.

Huygh G, Clement P, Dumez H, Schoffski P, Wildiers H, Selleslach J . Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2007; 2006:56282. PMC: 1820623. DOI: 10.1155/SRCM/2006/56282. View

20.

Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen J . Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2009; 10(9):1076-82. PMC: 2882053. DOI: 10.1038/ncb1767. View